Olaparib (Olaparib)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Other antineoplastic agents

Included in the formulation
  • Lynparza
    capsules inwards 
    AstraZeneca UK Ltd     United Kingdom
    • АТХ:

    L.01.X.X   Other antineoplastic agents

    L.01.X.X.46   Olaparib

    Pharmacodynamics:

    Inhibits poly (ADP-ribose) -polymerase (PARP), which leads to the death of cancer cells. Effective with hereditary BRCA1 or BRCA2 mutations in the ovaries, breast and prostate.

    Pharmacokinetics:

    After oral administration, fasted to 60% is absorbed in the gastrointestinal tract. The maximum concentration in blood plasma is reached after 1-3 hours. The connection with plasma proteins is 82%.

    Therapeutic effect develops after the reception. Metabolism in the liver.

    The half-life is 11.9 hours. Elimination with feces and kidneys.

    Indications:

    It is used for the treatment of ovarian cancer and fallopian tubes, primary peritoneal cancer of high degree of malignancy with a mutation of the BRCA gene.

    ICD-10

    II.C60-C63.C61   Malignant neoplasm of prostate

    II.C50.C50   Malignant neoplasm of breast

    II.C51-C58.C56   Malignant neoplasm of ovary

    Contraindications:

    Severe renal and hepatic insufficiency, simultaneous administration with inhibitors or inductors of CYP3A isoenzyme, pregnancy and lactation, age under 18, individual intolerance.

    Carefully:

    Hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category X. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Inside, 400 mg 2 times a day.

    The highest daily dose: 800 mg.

    The highest single dose: 400 mg.

    Side effects:

    Respiratory system: interstitial pneumonitis.

    Hemopoietic system: hemolytic anemia, rarely - myeloblastic leukemia.

    The cardiovascular system: vasculitis, myocarditis, angiopathy, cardiomyopathy.

    Digestive system: nausea, vomiting, diarrhea.

    Dermatological reactions: leukocytoclastic vasculitis, psoriasis, photosensitivity.

    Allergic reactions.

    Overdose:

    Increased side effects.

    Treatment is symptomatic.

    Interaction:

    Clinically significant interactions are not described.

    Special instructions:

    Monitoring of liver and kidney function.

    During treatment and within 3 months after its termination it is recommended to use reliable methods of contraception.

    In the treatment and within 6 months after its end It is not recommended to vaccinate with live vaccines.

    When taking the drug is not recommended driving and working with moving machinery.

    Instructions
    Up